Lonza to acquire Synaffix to strengthen ADC development
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
Read More
Tag: ADC
AZ signs $6bn deal with Daiichi Sankyo
The move secures AZ access to the Japanese drug giant’s experimental antibody drug conjugate
Read More
AZ/Daiichi’s breast cancer drug gets US priority review
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan has taken a step closer to US approval having been accepted for priority review by the US Food and Drug Administration (FDA) for breast cancer.
Read More
First patient dosed in ADCT-402 Phase I trial for lymphoma
ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca’s Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma.
Read More
GamaMabs licences AZ technology for new cancer therapy
French biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer.
Read More
UK firms link to develop ADCs for cancer
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Read More
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
Glythera launches Innovate UK-funded ADC project
UK biotech Glythera has announced the launch of a £1 million Innovate UK grant-funded project to develop next-generation antibody drug conjugates (ADCs) for difficult-to-treat tumours.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
